Evidence map›Paper›PMID 27527850›Full record

ArticleOncotarget2016

PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.

Wei Xing, Karen Dresser, Rui Zhang, Andrew M Evens, Hongbo Yu, Bruce A Woda, Benjamin J Chen

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. The Prognostic Impact of Tumor Microenvironment and Checkpoint Blockade-Associated Molecules (PD-1, PD-L1, CD163 and CD14) in Nodal Diffuse Large B-cell Lymphoma, NOS.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024
    Article
  6. Article
  7. Article
  8. Plasmablastic Lymphoma. A State-of-the-Art Review: Part 2-Focus on Therapy.Mediterranean journal of hematology and infectious diseases · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Wei XingDepartment of Pathology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, USA.
Karen DresserDepartment of Pathology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, USA.
Rui ZhangDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Andrew M EvensDivision of Hematology/Oncology, Tufts Medical Center, Boston, MA, USA.
Hongbo YuDepartment of Pathology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, USA.
Bruce A WodaDepartment of Pathology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, USA.
Benjamin J ChenDepartment of Pathology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, USA.
University of Massachusetts Chan Medical School · USUMass Memorial Medical Center · USBoston University · USTufts Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Programmed cell death ligand 1 (PD-L1) is a cell surface glycoprotein that regulates the cellular immune response and serves as a targetable immune checkpoint molecule. PD-L1 is expressed on tumor cells and the immune microenvironment of several human malignancies, including a subset of aggressive lymphomas. We sought to investigate further the clinical and pathologic features of EBV-negative diffuse large B-cell lymphoma (DLBCL) cases that express PD-L1. Immunohistochemical staining using an anti-PD-L1 monoclonal antibody was performed on DLBCL cases from 86 patients. These patients received standard chemotherapy treatment and were followed for up to 175 months. Overall, 14 cases (16%) were considered positive for PD-L1 in tumor cells. In comparison with PD-L1 negative cases, PD-L1 positive cases had a higher rate of non-GCB type (71% vs. 30%, P=0.0060), and higher Ann Arbor stage (II-IV) (100% vs. 73%, P=0.0327). No significant differences were seen in the immunohistochemical expression of BCL2, MYC, or Ki67. Patients with tumors expressing PD-L1 demonstrated inferior overall survival (OS) upon long term follow up (P=0.0447). Both age/sex-adjusted and multivariate analyses identified PD-L1 as an independent predictor for OS (P=0.0101 and P=0.0424). There was no significant difference, however, in terms of remission rates after first treatment, relapse rates, and progression free survival between the groups. Identification of DLBCL cases that express PD-L1 may serve to select a subset of patients that could further benefit from targeted immunotherapy.

Indexed as

AdolescentAdultAgedAged, 80 and overB7-H1 AntigenBiomarkers, TumorB-LymphocytesCohort StudiesFollow-Up StudiesHerpesvirus 4, HumanHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingPredictive Value of TestsB7-H1 AntigenBiomarkers, Tumordiffuse large B-cell lymphomaimmune checkpointimmunotherapyprogrammed cell death ligand 1

Identifiers

PMID27527850
PMCPMC5312363
OpenAlexW2496089957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.